US Capitol Capsule: What's life & limb worth? Gauging antibiotics' value
This article was originally published in Scrip
Executive Summary
Even though the economics of developing antibacterials may appear to be only one among the many topics set to be discussed at the 30-31 July workshop being convened by the FDA and the National Institutes of Health (NIH), the issue is key for companies in the space and expected to draw great interest.